Academic Journal

The Interplay Between HIF‐1α and EZH2 in Lung Cancer and Dual‐Targeted Drug Therapy

التفاصيل البيبلوغرافية
العنوان: The Interplay Between HIF‐1α and EZH2 in Lung Cancer and Dual‐Targeted Drug Therapy
المؤلفون: Jianmin Wang, Cheng Yang, Huashen Xu, Xinyu Fan, Lina Jia, Yang Du, Shougeng Liu, Wenjing Wang, Jie Zhang, Yu Zhang, Xiaoxue Wang, Zhongbo Liu, Jie Bao, Songping Li, Jingyu Yang, Chunfu Wu, Jing Tang, Guoliang Chen, Lihui Wang
المصدر: Advanced Science, Vol 11, Iss 7, Pp n/a-n/a (2024)
بيانات النشر: Wiley, 2024.
سنة النشر: 2024
المجموعة: LCC:Science
مصطلحات موضوعية: dual‐targeted drugs, feedback regulation, EZH2, HIF‐1α, lung cancer, Science
الوصف: Abstract Interactions between oncogenic proteins contribute to the phenotype and drug resistance. Here, EZH2 (enhancer of zest homolog 2) is identified as a crucial factor that mediates HIF‐1 (hypoxia‐inducible factor) inhibitor resistance. Mechanistically, targeting HIF‐1 enhanced the activity of EZH2 through transcription activation of SUZ12 (suppressor of zest 12 protein homolog). Conversely, inhibiting EZH2 increased HIF‐1α transcription, but not the transcription of other HIF family members. Additionally, the negative feedback regulation between EZH2 and HIF‐1α is confirmed in lung cancer patient tissues and a database of cell lines. Moreover, molecular prediction showed that a newly screened dual‐target compound, DYB‐03, forms multiple hydrogen bonds with HIF‐1α and EZH2 to effectively inhibit the activity of both targets. Subsequent studies revealed that DYB‐03 could better inhibit migration, invasion, and angiogenesis of lung cancer cells and HUVECs in vitro and in vivo compared to single agent. DYB‐03 showed promising antitumor activity in a xenograft tumor model by promoting apoptosis and inhibiting angiogenesis, which could be almost abolished by the deletion of HIF‐1α and EZH2. Notably, DYB‐03 could reverse 2‐ME2 and GSK126‐resistance in lung cancer. These findings clarified the molecular mechanism of cross‐regulation of HIF‐1α and EZH2, and the potential of DYB‐03 for clinical combination target therapy.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2198-3844
Relation: https://doaj.org/toc/2198-3844
DOI: 10.1002/advs.202303904
URL الوصول: https://doaj.org/article/fa2b2c700c7e4c0fa2cf0b1ae9bc1ab8
رقم الانضمام: edsdoj.fa2b2c700c7e4c0fa2cf0b1ae9bc1ab8
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:21983844
DOI:10.1002/advs.202303904